HSIC Henry ScheinWatchlist
Henry Schein News
Goldman Sachs Keeps Their Hold Rating on Henry Schein (HSIC)
Slew of Data Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Monday
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively traded Invesco QQQ Trust (QQQ) declined 0.5% in Monday's premarket activity, as investors await a slew
Express News | Henry Schein's Zahn Dental Becomes Exclusive Distributor Of Myerson's Innovative Trusana 3D Premium Denture System
Zahn Dental Exclusively Distributes Myerson's New Trusana 3D Premium Denture System
Zahn Dental, the dental laboratory business of Henry Schein, Inc. (NASDAQ:HSIC), announces its exclusive distribution of Myerson's newly launched Trusana Premium Denture System. The system is comprised of the
Henry Schein Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index for Eighth Consecutive Year
Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it received a score of 100 on the Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index (CEI), the nation's foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.
Earnings Call: Patterson Companies Adjusts Fiscal 2024 Guidance Amid Macroeconomic Challenges
Analysts Are Bullish on Top Healthcare Stocks: Henry Schein (HSIC), DocGo (DCGO)
Patterson Companies Tumbles as Revised FY24 Outlook Disappoints
Henry Schein to Present at Nasdaq's 49th Investor Conference
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at Nasdaq's 49th Investor
Stifel Reiterates Buy on Henry Schein, Maintains $75 Price Target
Stifel analyst Jonathan Block reiterates Henry Schein with a Buy and maintains $75 price target.
Jefferies U.S. Quant Portfolio - ROIC Stars and High Yield
Analysts Offer Insights on Healthcare Companies: Agilent (A), Henry Schein (HSIC) and Biogen (BIIB)
Henry Schein (HSIC) Q3 Earnings Analysis: A Medical Stock to Watch?
Express News | Henry Schein Gets Deficiency Notice From Nasdaq Regarding Requirement To Timely File Quarterly Report
Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announces that it received an expected notice (the "Notice") on November 13, 2023
These Analysts Slash Their Forecasts On Henry Schein After Q3 Results
Henry Schein Inc (NASDAQ:HSIC) posted downbeat sales results for its third quarter on Monday. Henry Schein reported quarterly sales of $3.16 billion, slightly missing the consensus of $3.21 billion.
What 5 Analyst Ratings Have To Say About Henry Schein
Analysts have provided the following ratings for Henry Schein (NASDAQ:HSIC) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings12110Last 30D010101M Ago11100
Barrington Cuts Price Target on Henry Schein to $82 From $90, Maintains Outperform Rating
Henry Schein (HSIC) has an average rating of hold and price targets ranging from $65 to $90, according to analysts polled by Capital IQ. Price: 68.51, Change: +1.01, Percent Change: +1.5
Morgan Stanley Maintains Underweight on Henry Schein, Lowers Price Target to $65
Morgan Stanley analyst Erin Wright maintains Henry Schein with a Underweight and lowers the price target from $69 to $65.
Henry Schein Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/14/2023 -5.11% Morgan Stanley $69 → $65 Maintains Underweight 11/10/2023 2.19% Stifel → $70 Upgrades Ho